Last reviewed · How we verify
ALZ-801
ALZ-801 is a dual A beta 42 and A beta 40 inhibitor.
ALZ-801 is a dual A beta 42 and A beta 40 inhibitor. Used for Alzheimer's disease.
At a glance
| Generic name | ALZ-801 |
|---|---|
| Sponsor | Alzheon Inc. |
| Drug class | Amyloid beta inhibitor |
| Target | Amyloid beta |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
It works by inhibiting the production of amyloid beta peptides, which are thought to contribute to the progression of Alzheimer's disease. By reducing the levels of these peptides, ALZ-801 aims to slow down the disease's progression.
Approved indications
- Alzheimer's disease
Common side effects
- Nausea
- Diarrhea
- Headache
Key clinical trials
- Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease (PHASE2)
- An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects (PHASE3)
- Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects (PHASE3)
- Single Dose Study of ALZ-801 Prototype Tablets (PHASE1)
- Multiple Ascending Dose Study of ALZ-801 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALZ-801 CI brief — competitive landscape report
- ALZ-801 updates RSS · CI watch RSS
- Alzheon Inc. portfolio CI